Arthroplasty

Arthrex Launches BunionPain.com to Educate Patients on Bunion Treatment Options

Retrieved on: 
Monday, December 5, 2022
Trauma, Ankle, Heredity, Bunion, Woman, PECA, Deformity, Spine, Quality, Patient, Science, Ford Motor Company, Pain, Multimedia, Education, OR, Arthroplasty, Institute for Quality and Efficiency in Health Care, Elective surgery, Schuberth, Foot, Medical device, Dentistry, Extremities

NAPLES, Fla., Dec. 5, 2022 /PRNewswire/ -- Arthrex, a global leader in minimally invasive orthopedic technology, launched BunionPain.com, the company's patient-focused website, focused on Arthrex's innovative procedure for minimally invasive bunion correction.

Key Points: 
  • Website focuses on patient education about causes, treatment with the Arthrex Minimally Invasive Bunionectomy
    NAPLES, Fla., Dec. 5, 2022 /PRNewswire/ --Arthrex, a global leader in minimally invasive orthopedic technology, launched BunionPain.com , the company's patient-focused website, focused on Arthrex's innovative procedure for minimally invasive bunion correction.
  • Our goal with BunionPain.com is to create an educational hub for those seeking information about the science of bunions, their potential treatment options and how they can connect with expert surgeons in their area," said Arthrex Senior Director of Extremities and Trauma Pete Denove.
  • Bunions, which can be hereditary or caused by footwear, affect an estimated 30% to 50% of Americans.
  • Lee M, Walsh J, Smith MM, Ling J, Wines A, Lam P.Hallux valgus correction comparing percutaneous chron/Akin (PECA) and open scarf/Akin osteotomies.Foot Ankle Int.

Arthrex Innovates Bunion Correction With Minimally Invasive Procedure

Retrieved on: 
Monday, December 5, 2022
Medicine, Bunion, Medical education, PECA, Spine, Edison Awards, Patient, Edison Award, Pain, Surgeon, Trauma, Multimedia, Consultant, Foot, Marketing, OR, Arthroplasty, Elective surgery, Dentistry, Medical device

NAPLES, Fla., Dec. 5, 2022 /PRNewswire/ -- Arthrex, a global leader in minimally invasive orthopedic technology, has launched the award-winning Arthrex Minimally Invasive Bunionectomy System to offer patients a better solution to traditional bunion surgery.

Key Points: 
  • NAPLES, Fla., Dec. 5, 2022 /PRNewswire/ -- Arthrex,a global leader in minimally invasive orthopedic technology,has launched the award-winning Arthrex Minimally Invasive Bunionectomy System to offer patients a better solution to traditional bunion surgery.
  • The Arthrex Bunionectomy System is designed to be an all-inclusive set to facilitate minimally invasive surgical bunion correction.
  • It is clinically proven to achieve the same or better corrective results than traditional surgery with less downtime, pain and swelling.1,2
    Performed through tiny incisions, this minimally invasive procedure means patients can achieve complete bunion correction and get back on their feet faster.
  • Arthrex Inc., headquartered in Naples, Florida, is a global leader in multi-specialty, minimally invasive surgical technology, medical research, manufacturing and medical education.

Arthrex, Richard Wolf Announce Partnership to Expand Comprehensive Operative Care Solutions

Retrieved on: 
Monday, November 28, 2022
Urology, Endoscopy, Elective surgery, Arthroplasty, Trauma, Multimedia, Partnership, Patient, Spine, Paola Lattus, Marketing, Surgeon, Synergy, Gynaecology, General surgery, OR, Health insurance, Medical device

NAPLES, Fla., Nov. 28, 2022 /PRNewswire/ -- Arthrex and Richard Wolf, global leaders in minimally invasive surgical technology and solutions, announced a U.S.-based partnership to offer comprehensive technology and product offerings in urology, gynecology and general surgery.

Key Points: 
  • "Arthrex and Richard Wolf are united in their missions to advance health care and improve patient outcomes.
  • Through this partnership, health care professionals in the U.S. will experience a comprehensive and complimentary line of surgical solutions for urology, gynecology and general surgery in a single package," said Arthrex Director of Global Endoscopy Jeremy Roberts.
  • "Richard Wolf is excited to engage in this collaboration in the U.S. with Arthrex," said Jim Fagan, U.S. Corporate Director of Sales and Marketing for Richard Wolf.
  • Richard Wolf is a full-service provider in endoscopy, offering a wide range of instrumentation and system solutions for minimally invasive medicine.

Mast Cell Levels May Explain Sex Differences in Osteoarthritis Pain

Retrieved on: 
Monday, November 14, 2022
Magnet, Hospital, Pain, Cell, Therapy, ACR, U.S. News & World Report, Stanford University School of Medicine, Hospital for Special Surgery, Rockefeller University, Blood, Knee, B cell, Health, Elective surgery, MS, Infection, Asthma, Weill Cornell Medicine, American Nurses Credentialing Center, Factor X, Synovial fluid, Patient, American College, News, MBBS, Osteoarthritis, Doctor of Philosophy, Database, Arthroplasty, HSS, Woman, Nursing, American College of Rheumatology, Multimedia, Long Island, Laboratory, Marie Cassidy, Organization, Physician, Allergy, Man, Rheumatology, Tissue, Education, Research, Synovial, The Hospital, Sex, Birth control, MD, Newsweek

"We studied synovial tissue removed at the time of total knee arthroplasty to look for a biological reason that may explain the difference in reported pain between sexes."

Key Points: 
  • "We studied synovial tissue removed at the time of total knee arthroplasty to look for a biological reason that may explain the difference in reported pain between sexes."
  • Basic research by other scientists has suggested a link between mast cells and osteoarthritis progression and pain.
  • They also found higher levels of a byproduct of mast cells called tryptase in synovial tissue from women than men, providing further evidence of increased mast cell activity.
  • "We hope our findings encourage other researchers to start thinking about biological factors that may contribute to sex differences in patient-reported pain in knee osteoarthritis," Dr. Orange said.

Worldwide Bone Cement Industry to 2027 - Heightening Applications of Bone Cement in the Healthcare Industry to Improve the Recovery of Patients is Aiding Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 8, 2022
Health, Biotechnology, Trauma, Most favoured nation, Augmented fifth, Arthroplasty, Prevalence, Research, Safety, Awareness, Patient, Fracture, CAGR, Health insurance, Antibiotics

According to the report, global bone cement market is growing at a CAGR of 6.1% between 2022 and 2027, aided by the heightening applications of bone cement in the healthcare industry to improve the recovery of patients from chronic fractures or bone injuries.

Key Points: 
  • According to the report, global bone cement market is growing at a CAGR of 6.1% between 2022 and 2027, aided by the heightening applications of bone cement in the healthcare industry to improve the recovery of patients from chronic fractures or bone injuries.
  • Bone cement is a compound which has a strong mechanical interlocking system that support artificial joints.
  • Available in injectable form, bone cement is minimally invasive and poses low risk of bone damage which makes it unique and reliable.
  • The increasing inclination towards less-invasive treatment procedures for greater safety is propelling the market growth for bone cement.

MicroPort Orthopedics and Pixee Medical Announce the Commercialization of its Orthopedic Surgery Technology in the U.S.

Retrieved on: 
Thursday, November 3, 2022
MicroPort, Arthroplasty, Elective surgery, Solution, Advance, FDA, Smartglasses, Surgeon, CEO, Technology, Efficiency, Patient, Quality of life, Hip, Motion, Partnership, Knee, Multimedia, Learning, ASC, Medical device, Dentistry, Hospital

ARLINGTON, Tenn., Nov. 3, 2022 /PRNewswire/ -- MicroPort Orthopedics, a global leader in orthopedic devices and technologies, today announces the expansion of its partnership with Pixee Medical through the commercialization of its combined surgical solution in the United States. Utilizing Pixee Medical's FDA-cleared augmented reality surgical application for assistance in total knee arthroplasty, the surgeon can achieve precision and control when implanting MicroPort Evolution® Medial-Pivot Knee Implant. This solution is currently being used in thousands of successful cases around the world including in Australia, Europe, and Asia. 

Key Points: 
  • The MicroPort Orthopedics Evolution Medial-Pivot Knee Implant delivers a high degree of stability and motion, leading to increased patient satisfaction1 and survivorship1.
  • Combining MicroPort's innovative devices with Pixee Medical's platform is allowing patients, worldwide, access to surgery solutions integrating top of the class technologies.
  • Pixee Medical's ambition is to empower all orthopedic surgeons with the latest breakthrough in precision surgery, to become digitally augmented surgeons.
  • Pixee Medical's augmented surgery platform is commercially available in Europe, Australia, and the USA for total knee arthroplasty with Knee+.

Exactech Connects Surgeons and Patients on Another Level with High NPS® and New Message Streams

Retrieved on: 
Monday, August 8, 2022
Technology, Medical Devices, Surgery, Other Technology, Health Technology, Telemedicine, Virtual Medicine, Software, Biotechnology, General Health, Health, Â, Multimedia, University of Maryland Rehabilitation & Orthopaedic Institute, Arthroscopy, Surgeon, Technology, YouTube, Percussion section, Hospital, NPS, Patient, Instagram, Company, Twitter, Arthroplasty, GPS, Physician, Knee, MD, LinkedIn, Rehabilitation, Hip, Active, Shoulder, Dentistry, Medicine, Health insurance, Pacific Ocean

View the full release here: https://www.businesswire.com/news/home/20220808005423/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220808005423/en/
    Exactech Connects Surgeons and Patients on Another Level with High NPS and New Message Streams (Photo: Business Wire)
    One of the first adopters of the new shoulder messaging stream is the Orthopedic Institute in South Dakota.
  • We have received amazing feedback from our patients about the exacCoach messaging, said Jason Hurd, MD, shoulder and elbow specialist.
  • It has been a great, easy-to-use technology that allows us to stay connected with our patients and keep them informed.
  • *Net Promoter, NPS, NPS Prism, and the NPS-related emoticons are registered trademarks of Bain & Company, Inc., Satmetrix Systems, Inc., and Fred Reichheld.

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Retrieved on: 
Wednesday, July 13, 2022
Parallel Walk Test, Technology, Knowledge, Method, Leg, Tissue, Safety, Soft tissue injury, Security (finance), Injury, Center, U.S. Securities and Exchange Commission, Berlin, TASE, Science, Walking, Engineering, Fracture, Therapy, Inflammation, Arthroplasty, Company, III, Patient, GLOBE, Private Securities Litigation Reform Act, Population, Ischemia, Legislation, Muscle, Nasdaq, Regeneration, Trial of the century, Regenerative medicine, Pressure, Tel Aviv Sourasky Medical Center, Osteoarthritis, HAS, Pharmaceutical industry, Phosphorus, Medical device, Aluminium, Dietary supplement, Pluristem Therapeutics

HAIFA, Israel, July 13, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (“Pluristem” or the “Company”), a leading biotechnology company, today announced topline results from its multinational double-blind, placebo-controlled phase III study. The Company designed the study to determine the efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for hip fracture. The study enrolled 240 patients in the United States, Europe, and Israel.

Key Points: 
  • The Company will host an analyst and investor call to discuss the phase III muscle regeneration following hip fracture surgery topline results on July 14 at 9:00 a.m.
  • ET; for registration: https://pluristem.zoom.us/webinar/register/WN_kp_CwQQtR-aFtjAXrdiJpA
    HAIFA, Israel, July 13, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (Pluristem or the Company), a leading biotechnology company, today announced topline results from its multinational double-blind, placebo-controlled phase III study.
  • The Company designed the study to determine the efficacy, safety, and tolerability of intramuscular administration of allogeneic PLX-PAD cells for the treatment of muscle injury following arthroplasty for hip fracture.
  • This new data confirms the results demonstrated in Pluristems phase I/II study .

Improved Shoulder Outcomes and Knee Balance Among Findings in New Exactech Research

Retrieved on: 
Wednesday, June 29, 2022
Technology, Biotechnology, Men, Health, Consumer, Other Health, Other Technology, Software, Children, General Health, Health Technology, Women, Seniors, Clinical Trials, Newton, GPS, Deep learning, Surgeon, Science, Patient, LinkedIn, Intelligence, Journal, Research, Percussion section, Active, Shoulder, CAOS, Ligamentous laxity, Review, YouTube, Supplement, Technology, Instagram, Twitter, Physician, Learning curve, International Society, Multimedia, Algorithm, Gaps, Hospital, Dentistry, Medical imaging, Medical device, Silviculture, Wood drying, Arthroplasty, Pacific Ocean

View the full release here: https://www.businesswire.com/news/home/20220629005291/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220629005291/en/
    Improved Shoulder Outcomes and Knee Balance Among Findings in New Exactech Research (Photo: Business Wire)
    Leading the podium for Exactech was a first-of-its-kind clinical outcomes study of navigated shoulder arthroplasty that showed reduced postoperative complications, revision rates and adverse events.1 Based on two-year minimum clinical outcomes collected on both anatomic and reverse total shoulder arthroplasty patients through the worlds largest single-shoulder prosthesis outcomes database, the study demonstrated that ExactechGPS -navigated groups experienced improved clinical outcomes compared to non-navigated groups.
  • These powerful new findings highlight the impressive work Exactech is conducting with smart technology, said Darin Johnson, Exactech President.
  • At CAOS, we presented improved short-term functional outcomes research, with thousands of patients, leveraging our GPS technology for shoulder.
  • Ability to Achieve Mediolateral Gap Balance with Instrumented Navigated Total Knee Arthroplasty A Review of the First 150 Cases.

Force Therapeutics Selected to Optimize Care Delivery at Ambulatory Surgical Centers

Retrieved on: 
Friday, June 17, 2022
Education, Hartford Hospital, Data analysis, Length of stay, CSA, CEO, Joint Commission, Research, Leadership, OASC, Orthopedic surgery, Force, Accreditation, Patient, Bone, Center, Center of excellence, Joint, Collection, The Force, Therapy, Hip, Patient satisfaction, Risk, Medical device, Hospital, Medicine, Arthroplasty

NEW YORK, June 17, 2022 /PRNewswire/ -- Today Force Therapeutics announced that Constitution Surgery Alliance (CSA), an operator of 21 ambulatory surgical centers throughout the Northeast, is implementing its digital care management platform to reduce cost and quality variation for all total joint replacements and spinal surgeries. The Force Therapeutics platform delivers video-based education and virtual physical therapy, while providing clinicians with real-time progress updates for proactive monitoring of patients' recovery.

Key Points: 
  • Following national trends, approximately 40% of Hartford Hospital's orthopedic surgery volume is moving from the inpatient setting to outpatient surgery centers.
  • By March 2023, CSA will implement the Force Therapeutics platform at two additional surgery centers, with plans to expand geographically to centers in Massachusetts, Pennsylvania, and Virginia.
  • "We're pleased to be selected as Constitution Surgery Alliance's partner in quality orthopedic care," said Bronwyn Spira, founder and CEO of Force Therapeutics.
  • "The Force platform will help CSA's surgery centers optimize how they run and manage their practices.